Whose side are you on?

Data on the prognostic and predictive values of primary tumor sidedness in metastatic colorectal cancer (mCRC) patients have, over the last year or so, been reported at oncology meetings and, in some cases, published subsequently as full articles. The present edition of Annals of Oncology includes two major articles, one on the impact of tumor sidedness in three panitumumab trials [1] and the other a meta-analysis of published and unpublished data from randomized controlled trials, comparing chemotherapy plus anti-epidermal growth factor receptors (EGFRs) with chemotherapy alone or combined with bevacizumab [2]. The vast majority of these trials deal with treatment-naive RAS wild-type mCRC patients, except for one in the meta-analysis which is testing chemotherapy plus or minus panitumumab in a second-line setting.

http://ift.tt/2hmAUxd